Treatment strategies of hospitalized patients with coronavirus disease-19.
Adult
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
COVID-19
China
/ epidemiology
Chloroquine
/ analogs & derivatives
Coronavirus Infections
/ epidemiology
Drug Combinations
Drugs, Chinese Herbal
/ therapeutic use
Female
Glucocorticoids
/ therapeutic use
Hospitalization
Humans
Immunologic Factors
/ therapeutic use
Indoles
/ therapeutic use
Interferons
/ therapeutic use
Lopinavir
/ therapeutic use
Male
Middle Aged
Oxygen
/ therapeutic use
Pandemics
Pneumonia, Viral
/ epidemiology
Respiration, Artificial
Retrospective Studies
Ritonavir
/ therapeutic use
SARS-CoV-2
gamma-Globulins
/ therapeutic use
COVID-19
coronasvirus disease-19
epidemiological and clinical characteristics
outside Wuhan
prognosis
treatment strategies
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
17 06 2020
17 06 2020
Historique:
received:
31
03
2020
accepted:
14
05
2020
pubmed:
20
6
2020
medline:
21
7
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
With the outbreak of coronavirus disease-19 (COVID-19), Changsha faced an increasing burden of treating the Wuhan migrants and their infected patients. This study is a retrospective, single-center case series of the 238 consecutive hospitalized patients with confirmed COVID-19 at the First Hospital of Changsha city, China, from 01/21 to 02/14, 2020; the final date of follow-up was 02/27, 2020. Of 238 patients 43.7% visited Wuhan, 58.4% got in touch with Wuhan people, and 47.5% had contacted with diagnosed patients. 37.8% patients had family members infected. 190 cases had mild / general disease, and 48 cases had severe / critical disease. Compared to mild or general patients, more severe or critical patients visited Wuhan (59.6% vs 40.2%;
Identifiants
pubmed: 32554861
pii: 103370
doi: 10.18632/aging.103370
pmc: PMC7343487
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antiviral Agents
0
Drug Combinations
0
Drugs, Chinese Herbal
0
Glucocorticoids
0
Immunologic Factors
0
Indoles
0
Xuebijing
0
gamma-Globulins
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
chloroquine diphosphate
6E17K3343P
Chloroquine
886U3H6UFF
Interferons
9008-11-1
umifenovir
93M09WW4RU
Ritonavir
O3J8G9O825
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11224-11237Commentaires et corrections
Type : ErratumIn
Références
Radiology. 2020 Apr;295(1):202-207
pubmed: 32017661
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Feb 17;54(0):E005
pubmed: 32064855
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32010938
PLoS One. 2014 Jul 29;9(7):e102429
pubmed: 25072598
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 06;43(0):E005
pubmed: 32026671
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1022-1023
pubmed: 32060619
JAMA. 2020 Feb 7;:
pubmed: 32031570
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-170
pubmed: 32053579
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Front Microbiol. 2019 Dec 03;10:2752
pubmed: 31849894
JAMA. 2020 Feb 5;:
pubmed: 32022836
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327